肾综合征出血热Ⅰ型灭活疫苗预防接种成本效益和效果分析  

Cost Benefit and Effectiveness Analysis of Type Ⅰ Inactivated Vaccine against Hemorrhagic Fever with Renal Syndrome

作　　者：阮玉华[1,2] 徐校平[1,2] 童政 周卫群[1,2] 邵守坤 顾惠心 徐志一 

机构地区：[1]上海医科大学流行病学教研室 [2]浙江省建德市卫生防疫站

出　　处：《中国公共卫生》1999年第7期603-605,共3页Chinese Journal of Public Health

摘　　要：对肾综合征出血热Ⅰ型灭活疫苗进行成本效益和效果分析，为肾综合征出血热免疫预防策略的制定提供依据。以建德市肾综合征出血热Ⅰ型灭活疫苗现场效果考核资料为基础，分５个不同年龄组队列，计算各组的效益费用比（ＢＣＲ）和费用效果比（ＣＥＲ）。各年龄组ＢＣＲ和ＣＥＲ均分别小于１和大于０。３０～３９岁年龄组ＣＥＲ值１１０８０８２元最小，接近于人均国民生产总值（１０８万元），其他各组ＣＥＲ均较大，灵敏度分析显示疫苗费、保护率和保护期对ＣＥＲ和ＢＣＲ影响大。高危人群２０～２９、３０～３９和４０～４９岁年龄组ＣＥＲ均小于人均国民生产总值。结论：预防接种肾综合征出血热灭活疫苗未获正效益；３０～３９岁年龄组，其次是４０～４９岁和２０～２９岁年龄组是首选接种人群；１５～５９岁高危人群均需接种疫苗，其中２０～４９岁是重点接种人群。Cost benenfit and effectiveness analysis of type Ⅰ inactivated vaccine against hemorrhagic fever with renal syndrome was conducted and it was guildline for strategy of immunizing with type Ⅰ inactiveated vaccine against HFRS.Based on materials of epidemilogy efficacy of type Ⅰ inactivated vaccines against HFRS in Jiande county.Benefit cost ratio(BCR) and Cost effective ratio(CER)were estimated for 5 cohorts of different age groups.BCR and CER of all age groups were under 1 and above respectively.CER of 30～39 age group (11080.82 yuan REM)was almost to the average per capital GDP(10800 yuan) and CER of other age groups was larger.Sensitivity analysis showed that vaccine cost,protect rate and protect period of vaccine affected CER and BCR more.CER of 20～29,30～39 and 40～49 age groups with high risk were under GDP.It couldn't obtain benefit of inactivated vaccines inoculated against HFRS;The first people immunlized with inactivated vaccine against HFRS was 30～39 age group and the next peoples were 40～49 age and 20～29 age group;Vaccine can be used to cover the population of high risk of age 15～59 years old ,but the key population of vaccine gived ws 20～49 age groups.

关 键 词：肾综合征出血热 灭活疫苗 预防接种 成本效果 分析 

分 类 号：R512.803[医药卫生—内科学]